J&J's (JNJ) Janssen Reports Significant Phase 3 Data from Golimumab on Radiographic Progression in RA Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/21/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY
6. AVGO
7. SPCX
8. OSIS
9. BJ
10. A

Go back to J&J's (JNJ) Janssen Reports Significant Phase 3 Data from Golimumab on Radiographic Progression in RA Patients
Johnson & Johnson (NYSE: JNJ) Delayed: 271.49 +4.12 (1.54%)
Previous Close $267.37    52 Week High $126.07 
Open $267.83    52 Week Low $94.28 
Day High $272.66    P/E 56.44 
Day Low $267.00    EPS $4.81 
Volume 2,095,018